Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses). Burrill's technical and venture investing competence spans the entire spectrum of life sciences.
Burrill & Company has created a unique and highly effective platform for generating deal flow, assessing the scientific, commercial and investment viability of potential transactions, executing transactions, creating value in portfolio companies, and exiting. Our capital base has been provided by over 17 large corporate partners, plus a larger group of financial institutions.
Focused on the markets outside of the United States, Burrill International Group (BIG) is an integral part of Burrill & Company. BIG’s business activities are concentrated in the following countries and regions:
Greater China (Mainland China, Taiwan and Hong Kong)
India
Japan
Malaysia
Korea
Australia and New Zealand
Canada
Middle East
Russia and Eastern Europe
